Impressive IB performance, robust trading and lower rates will likely support Morgan Stanley's Q4 earnings.
Morgan Stanley (MS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan Stanley's top pick for 2025. He highlights the robust growth potential of Eli Lilly's drug Zepbound, which could become a $100 billion market opportunity.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Morgan Stanley (MS) reachead $126.88 at the closing of the latest trading day, reflecting a -1.37% change compared to its last close.
Morgan Stanley (MS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks.com users have recently been watching Morgan Stanley (MS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The latest trading day saw Morgan Stanley (MS) settling at $124.45, representing a +0.82% change from its previous close.
Morgan Stanley (MS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Morgan Stanley (MS) concluded the recent trading session at $127.74, signifying a -1% move from its prior day's close.
Here is how Morgan Stanley (MS) and Banc of California (BANC) have performed compared to their sector so far this year.
Morgan Stanley (MS) concluded the recent trading session at $127.59, signifying a +0.63% move from its prior day's close.